Brian Peskin is a theoretical research scientist specializing in lipids-based pharmacognosy—a class of drug derived from plant-based sources; specifically, seed oils. A notable benefit of this approach is the minimization/elimination of harmful side effects. He focuses specifically on the modulation of physiologically targeted essential fatty acids (EFAs) — termed Parent Essential Oils (PEOs) — and their eicosanoid metabolites. He is a translational science expert with a long-term interest in diabetes and its underlying pathophysiology. In 2002, he began extensive research on the relationship of PEOs and their metabolites to cancer and cardiovascular disease. Mr. Peskin’s work is focused on pathways that maximize oxygen delivery and blood flow to the human cell and maximizing tissue functionality.